

SWISS BIOTECH SUCCESS STORY



The origins of Biogen are in Switzerland, where the company was founded in Geneva in 1978

Biogen is the world third largest biotechnology company with 7,000 employees in 30 countries

From its foundation in Geneva until its recent return to Switzerland with a CHF 1.5bn investment in a new plant, the company's successes have many Swiss traits

The next-generation biologic manufacturing facility in Luterbach will create up to 600 new jobs



SWISS MARKERS AT BIOGEN

Founded in Geneva 1978

Established international headquarters in Zug in 2004

Planned opening of major production site in Luterbach in 2019





KNOWLEDGE

Innovative scientific research with the goal to defeat devastating neurological diseases




INDICATIONS

Therapies for serious medical conditions with few or no treatment options: multiple sclerosis, spinal muscular atrophy, biosimilars of advanced biologics



PIPELINE

Aducanumab: monoclonal antibody currently in Phase III to treat early forms of Alzheimer's disease
Compound licensed from and developed in collaboration with Neurimmune of Schlieren



SUCCESS CATEGORIES

- ★ Completed achievement with lasting impact
- ★ Scientific breakthrough
- ★ New technology
- ★ Strong impact on society
- ★ Product approval and sustainable revenues
- ☆ Important IP, innovative deal-making, acquisition
- ★ Involvement of one or more Swiss citizen
- ★ Swiss-based company/institution
- ★ Creation of jobs in Switzerland
- ☆ Other aspect with a direct link to Switzerland
- ★ Enabler for the biotech industry
- ★ Swissness: Think global, made in Switzerland